Profile data is unavailable for this security.
About the company
SNDL Inc., through its wholly owned subsidiaries, is a vertically integrated cannabis company and a private-sector liquor and cannabis retailer in Canada. Its retail banners include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds and Spiritleaf. With products available in licensed cannabis retail locations nationally, its consumer-facing cannabis brands include Top Leaf, Contraband, Palmetto, Bon Jak, La Plogue, Versus, Value Buds, Grasslands, Vacay, Pearls by Gron, No Future and Bhang Chocolate. Its liquor retail segment includes the sales of wines, beers and spirits. Its cannabis retail segment includes the sales of cannabis products and accessories through corporate-owned and franchised cannabis retail operations. Its cannabis operations segment operates as a licensed producer that grows cannabis using indoor facilities and manufactures cannabis products, providing cannabis processing services. Its investments segment includes deployment of capital to investment opportunities.
- Revenue in USD (TTM)695.75m
- Net income in USD-67.47m
- Incorporated2006
- Employees2.60k
- LocationSNDL Inc919 11 AVENUE SW, SUITE 300Calgary T2R1P3CanadaCAN
- Phone+1 (403) 948-5227
- Fax+1 (403) 948-5227
- Websitehttps://www.sndl.com/
More ▼
Mergers & acquisitions
| Acquired company | since announced | Transaction value |
|---|---|---|
| 1CM Inc-Cost Cannabis & T Cannabis Locations(32) | -- | 22.58m |
Data delayed at least 15 minutes, as of Mar 03 2026.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| X4 Pharmaceuticals Inc | 33.98m | -95.10m | 291.16m | 143.00 | -- | 1.36 | -- | 8.57 | -10.50 | -10.50 | 2.94 | 2.45 | 0.1989 | 1.75 | 25.37 | 237,615.40 | -55.66 | -55.04 | -65.82 | -63.45 | 83.24 | -- | -279.86 | -6,897.81 | 5.48 | -19.26 | 0.5525 | -- | -- | -- | 62.98 | -- | 111.28 | -- |
| AC Immune SA | 5.59m | -91.97m | 292.19m | 133.00 | -- | 3.66 | -- | 52.23 | -0.9152 | -0.9152 | 0.0557 | 0.7958 | 0.021 | -- | 0.3392 | 42,062.93 | -34.57 | -27.41 | -66.37 | -30.60 | -- | -- | -1,643.94 | -505.58 | -- | -- | 0.0695 | -- | 84.51 | -24.38 | 6.12 | -- | -21.11 | -- |
| Opus Genetics Inc | 14.63m | -68.20m | 293.10m | 18.00 | -- | 45.97 | -- | 20.03 | -1.76 | -1.76 | 0.2952 | 0.0925 | 0.3825 | -- | 3.85 | 812,944.40 | -178.28 | -76.30 | -330.00 | -86.90 | -- | -- | -466.09 | -185.79 | -- | -- | 0.1518 | -- | -42.30 | -- | -476.13 | -- | -- | -- |
| Puma Biotechnology Inc | 228.37m | 31.11m | 315.94m | 179.00 | 10.17 | 2.40 | 7.51 | 1.38 | 0.6104 | 0.6104 | 4.51 | 2.59 | 1.06 | 8.17 | 5.33 | 1,275,816.00 | 14.48 | 4.80 | 24.66 | 8.38 | 74.53 | 74.14 | 13.62 | 4.58 | 1.93 | 14.66 | 0.1473 | 0.00 | -0.9099 | 0.2881 | 2.75 | -- | -67.65 | -- |
| Akebia Therapeutics Inc | 236.20m | -5.35m | 326.81m | 194.00 | -- | 9.93 | -- | 1.38 | -0.0179 | -0.0179 | 0.8976 | 0.1229 | 0.791 | 2.55 | 5.80 | 1,217,505.00 | -1.79 | -27.07 | -3.03 | -45.24 | 82.83 | 78.83 | -2.26 | -45.92 | 1.46 | 1.07 | 0.8558 | -- | 47.46 | -4.33 | 92.30 | -- | 91.19 | -- |
| SNDL Inc | 695.75m | -67.47m | 393.82m | 2.60k | -- | 0.49 | -- | 0.566 | -0.2567 | -0.2567 | 2.66 | 3.12 | 0.6893 | 5.39 | 37.40 | 267,186.20 | -6.69 | -18.89 | -7.19 | -20.74 | 27.03 | 22.55 | -9.71 | -40.39 | 3.54 | -0.1287 | 0.1237 | -- | 1.26 | 70.67 | 43.62 | -- | -39.69 | -- |
| Elite Pharmaceuticals Inc | 140.12m | 43.41m | 414.11m | 68.00 | 9.94 | 5.14 | 9.20 | 2.96 | 0.0387 | 0.0387 | 0.1268 | 0.0748 | 1.29 | 3.03 | 4.18 | 2,060,564.00 | 39.98 | 13.18 | 45.86 | 16.01 | 51.06 | 47.19 | 30.98 | 13.97 | 5.44 | -- | 0.0517 | 0.00 | 48.42 | 36.10 | -121.46 | -- | 135.38 | -- |
| Enanta Pharmaceuticals Inc | 66.98m | -71.54m | 427.16m | 120.00 | -- | 3.37 | -- | 6.38 | -3.20 | -3.20 | 2.89 | 4.36 | 0.1975 | -- | 8.26 | 558,166.70 | -21.10 | -26.15 | -24.48 | -29.36 | -- | -- | -106.80 | -134.68 | -- | -- | 0.5181 | -- | -3.42 | -11.81 | 29.43 | -- | 54.92 | -- |
| SIGA Technologies Inc | 172.25m | 74.47m | 445.42m | 46.00 | 6.01 | 2.19 | 5.93 | 2.59 | 1.03 | 1.03 | 2.40 | 2.84 | 0.8069 | 0.7425 | 23.63 | 3,744,558.00 | 34.88 | 27.72 | 39.21 | 33.36 | 76.29 | 86.06 | 43.23 | 44.28 | 7.24 | -- | 0.00 | 37.70 | -0.8561 | 38.99 | -13.01 | -- | 7.85 | -- |
| Invivyd Inc | 50.04m | -59.86m | 456.82m | 99.00 | -- | 3.73 | -- | 9.13 | -0.4736 | -0.4736 | 0.3778 | 0.4341 | 0.3324 | -- | 5.56 | 505,444.40 | -39.76 | -- | -67.24 | -- | 93.34 | -- | -119.63 | -- | -- | -- | 0.00 | -- | -- | -- | 14.46 | -- | -- | -- |
| Emergent Biosolutions Inc | 788.90m | 75.90m | 461.80m | 900.00 | 6.89 | 0.807 | 2.65 | 0.5854 | 1.29 | 1.29 | 14.20 | 11.05 | 0.5369 | 1.06 | 5.83 | 876,555.60 | 5.17 | -5.03 | 5.90 | -6.47 | 54.58 | 49.01 | 9.62 | -9.76 | 3.15 | 1.85 | 0.5324 | -- | -0.5432 | -1.15 | 74.94 | -- | -25.06 | -- |
| Eton Pharmaceuticals Inc | 70.32m | -6.68m | 467.97m | 31.00 | -- | 20.24 | -- | 6.66 | -0.2491 | -0.2491 | 2.63 | 0.8624 | 1.00 | 3.64 | 7.53 | 2,268,258.00 | -9.52 | -27.81 | -17.48 | -37.96 | 51.36 | 68.16 | -9.50 | -38.41 | 1.25 | 0.2114 | 0.5677 | -- | 23.29 | 109.83 | -308.44 | -- | 40.24 | -- |
| Zevra Therapeutics Inc | 84.39m | 35.33m | 501.61m | 59.00 | 15.08 | 3.76 | 12.34 | 5.94 | 0.591 | 0.591 | 1.54 | 2.37 | 0.3656 | -- | 6.85 | 1,430,305.00 | 15.30 | -37.95 | 17.62 | -48.83 | 93.88 | -- | 41.86 | -193.51 | 8.57 | -9.57 | 0.3153 | -- | -14.02 | 12.96 | -129.13 | -- | 196.92 | -- |
| Aquestive Therapeutics Inc | 43.40m | -68.98m | 502.65m | 142.00 | -- | -- | -- | 11.58 | -0.7031 | -0.7031 | 0.4377 | -0.0338 | 0.3173 | 2.31 | 4.15 | 305,612.70 | -50.44 | -70.67 | -59.26 | -110.99 | 60.28 | 65.92 | -158.95 | -92.17 | 5.62 | -7.42 | 1.03 | -- | 13.80 | 1.82 | -460.83 | -- | -24.84 | -- |
Data as of Mar 03 2026. Currency figures normalised to SNDL Inc's reporting currency: US Dollar USD
16.78%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 12.39m | 4.81% |
| Cannell Capital LLCas of 31 Dec 2025 | 8.76m | 3.40% |
| Tidal Investments LLCas of 31 Dec 2025 | 5.17m | 2.01% |
| Arrowstreet Capital LPas of 31 Dec 2025 | 4.09m | 1.59% |
| AdvisorShares Investments LLCas of 31 Dec 2025 | 3.64m | 1.41% |
| Citadel Securities LLCas of 31 Dec 2025 | 2.16m | 0.84% |
| Global X Investments Canada, Inc.as of 31 Jan 2026 | 1.92m | 0.75% |
| Global X Management Co. LLCas of 31 Dec 2025 | 1.91m | 0.74% |
| Jane Street Capital LLCas of 31 Dec 2025 | 1.81m | 0.70% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2025 | 1.37m | 0.53% |
More ▼
Data from 31 Dec 2025 - 26 Feb 2026Source: FactSet Research Systems Inc.
